MBIO

NASD Mustang Bio, Inc.
Sep 30, 2026 · 3:02 PM ET DELAYED Market Open

$0.4687 ↓ -0.0109 (-2.27%) Trading Down from the previous close of $0.4796, $0.0062 below the day’s high of $0.4749

YTD change
-52.22%
vs 20-day SMA
-10.38%
vs 200-day SMA
-38.77%

Price ranges

Previous day
$0.4700 $0.5069
open $0.5069 close $0.4796
-$0.0273 (-5.39%)
Today
$0.4578 $0.4749
open $0.4750 now $0.4687
-$0.0063 (-1.33%)
Past week
$0.4700 $0.5500
from $0.5310 now $0.4687
-$0.0623 (-11.73%)
Past month
$0.4662 $0.5609
from $0.5375 now $0.4687
-$0.0688 (-12.80%)
This year
$0.4578 $1.2000
from $0.9810 now $0.4687
-$0.5123 (-52.22%)

Price & Performance

-0.25 (-33.86%) / 6M

$0.4541$0.5772$0.7004$0.8235Mar 30Jun 30Sep 29

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 100.0% away from all-time highs of $10,012.5000
  • MBIO is down 52% since the beginning of the year
  • MBIO is down 69% over the past 12 months
  • MBIO is down 13% over the past 1 month
  • 1% of all MBIO investors are betting against MBIO

MBIO reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -68.4%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.1592
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Enterprise value $-11920900.0
Beta 2.68

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$15.2M
DebtN/A
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $3.6M

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Waltham, MA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $423.64 +1.32%
MRNA Moderna, Inc. $203.46 +3.13%
RVMD Revolution Medicines, Inc. $204.48 +1.36%
ROIV Roivant Sciences Ltd. $36.50 -1.30%
BNTX BioNTech SE Sponsored ADR $98.57 -0.51%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.